Aytu BioPharma (NASDAQ:AYTU) Stock Rating Upgraded by Wall Street Zen

Aytu BioPharma (NASDAQ:AYTU) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Ascendiant Capital Markets upped their target price on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Finally, Zacks Research cut Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.33.

Aytu BioPharma Price Performance

NASDAQ:AYTU opened at $2.39 on Friday. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $3.07. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16. The firm’s 50-day simple moving average is $2.52 and its 200 day simple moving average is $2.34. The firm has a market cap of $25.64 million, a price-to-earnings ratio of -0.62 and a beta of 0.37.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.79). Aytu BioPharma had a negative return on equity of 28.22% and a negative net margin of 39.02%.The business had revenue of $15.17 million for the quarter, compared to analyst estimates of $12.17 million.

Institutional Investors Weigh In On Aytu BioPharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC acquired a new position in Aytu BioPharma during the 2nd quarter worth approximately $78,000. Stonepine Capital Management LLC grew its stake in shares of Aytu BioPharma by 75.3% during the second quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock worth $1,772,000 after buying an additional 348,955 shares during the last quarter. AWM Investment Company Inc. acquired a new position in shares of Aytu BioPharma during the second quarter worth $1,351,000. Persistent Asset Partners Ltd bought a new position in shares of Aytu BioPharma in the 3rd quarter valued at $117,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma in the 3rd quarter valued at $58,000. 33.49% of the stock is owned by institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.